CN112074283A - 使用韦荣氏球菌属细菌治疗癌症和免疫病症的组合物和方法 - Google Patents

使用韦荣氏球菌属细菌治疗癌症和免疫病症的组合物和方法 Download PDF

Info

Publication number
CN112074283A
CN112074283A CN201980011880.3A CN201980011880A CN112074283A CN 112074283 A CN112074283 A CN 112074283A CN 201980011880 A CN201980011880 A CN 201980011880A CN 112074283 A CN112074283 A CN 112074283A
Authority
CN
China
Prior art keywords
carcinoma
bacterial
veillonella
protein
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980011880.3A
Other languages
English (en)
Chinese (zh)
Inventor
B·古德曼
B·波斯
C·J·H·达维特
M·西佐瓦
S·M·R·卡尔顿
A·伊塔诺
H·波尼奇特拉
T·A·科马克
K·拉马尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epiva Biosciences Inc
Original Assignee
Epiva Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epiva Biosciences Inc filed Critical Epiva Biosciences Inc
Publication of CN112074283A publication Critical patent/CN112074283A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/04—Filters; Permeable or porous membranes or plates, e.g. dialysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/10—Separation or concentration of fermentation products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Sustainable Development (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
CN201980011880.3A 2018-02-06 2019-02-06 使用韦荣氏球菌属细菌治疗癌症和免疫病症的组合物和方法 Pending CN112074283A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862626789P 2018-02-06 2018-02-06
US62/626789 2018-02-06
US201862666944P 2018-05-04 2018-05-04
US62/666944 2018-05-04
US201862703269P 2018-07-25 2018-07-25
US62/703269 2018-07-25
PCT/US2019/016763 WO2019157003A1 (en) 2018-02-06 2019-02-06 Compositions and methods for treating cancer and immune disorders using veillonella bacteria

Publications (1)

Publication Number Publication Date
CN112074283A true CN112074283A (zh) 2020-12-11

Family

ID=65767281

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980011880.3A Pending CN112074283A (zh) 2018-02-06 2019-02-06 使用韦荣氏球菌属细菌治疗癌症和免疫病症的组合物和方法

Country Status (13)

Country Link
US (2) US11090341B2 (cg-RX-API-DMAC7.html)
EP (1) EP3749340A1 (cg-RX-API-DMAC7.html)
JP (1) JP7402805B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200118100A (cg-RX-API-DMAC7.html)
CN (1) CN112074283A (cg-RX-API-DMAC7.html)
AU (1) AU2019217526A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020015639A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090166A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020010956A2 (cg-RX-API-DMAC7.html)
MX (1) MX2020008244A (cg-RX-API-DMAC7.html)
SA (1) SA520412543B1 (cg-RX-API-DMAC7.html)
TW (1) TW201945015A (cg-RX-API-DMAC7.html)
WO (1) WO2019157003A1 (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114796264A (zh) * 2021-01-27 2022-07-29 北京北工大科技园有限公司 金络合物在制备治疗新型冠状病毒肺炎的药物中的应用
CN115990260A (zh) * 2022-12-09 2023-04-21 中国药科大学 一种用于抗肿瘤的联用组合药物
CN116249540A (zh) * 2020-07-21 2023-06-09 伊夫罗生物科学公司 小韦荣氏球菌菌株作为神经炎性疾病的口服疗法
CN116355785A (zh) * 2022-09-29 2023-06-30 南京市儿童医院 一株小韦荣氏球菌及其在制备诊断和治疗口腔鳞状细胞癌产品中的应用
CN117462662A (zh) * 2022-07-29 2024-01-30 中国科学院上海药物研究所 一种天花粉蛋白融合疫苗及其制备方法和应用
TWI859033B (zh) * 2023-12-18 2024-10-11 安益藥業股份有限公司 一種診斷犬科動物胰臟炎的方法與試劑組與一種使用醯基肉鹼作為診斷犬科動物胰臟炎之用途

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100420A1 (en) * 2015-12-08 2017-06-15 Mayo Foundation For Medical Education And Research Biomarkers for predicting clostridium difficile infection treatment outcome
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
JP2022520999A (ja) * 2019-02-22 2022-04-04 エヴェロ バイオサイエンシズ,インコーポレーテッド 細菌の膜調製物
CA3153020A1 (en) * 2019-09-12 2021-03-18 Jothi Amaranath Govindan Compositions and methods for characterizing a microbiome
TW202140050A (zh) * 2020-01-10 2021-11-01 美商艾弗洛生物科技股份有限公司 使用小韋榮氏球菌進行治療的組成物及方法
CN115551486A (zh) * 2020-04-17 2022-12-30 伊夫罗生物科学公司 具有改善的崩解谱的固体剂型
WO2022051494A1 (en) * 2020-09-03 2022-03-10 Evelo Biosciences, Inc. Compositions and methods for resolution of inflammation
TW202233214A (zh) 2020-11-06 2022-09-01 美商艾弗洛生物科技股份有限公司 使用小韋榮氏球菌細菌誘導免疫效應
JP2024501481A (ja) 2020-12-14 2024-01-12 エヴェロ バイオサイエンシズ,インコーポレーテッド 細胞外小胞調製物
EP4306119A4 (en) * 2021-03-08 2025-03-19 Juntendo Educational Foundation Composition and improving agent having inflammation-suppressing action
TW202304415A (zh) * 2021-04-08 2023-02-01 美商艾弗洛生物科技股份有限公司 含有細菌的藥物製劑
AU2021468875A1 (en) * 2021-10-11 2024-05-30 Vastu Vihar Biotech Private Limited An anti-inflammatory composition and a method of obtaining the same
WO2023068857A1 (ko) * 2021-10-20 2023-04-27 주식회사 고바이오랩 항암 활성을 갖는 신규 박테리아 균주 및 이를 이용한 암의 완화, 예방 또는 치료용 조성물
WO2023114300A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Fournierella massiliensis bacteria extracellular vesicle preparations
WO2023114295A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Veillonella parvula bacteria extracellular vesicle preparations
CN114146098A (zh) * 2021-12-31 2022-03-08 中山大学 Veillonella atypica在制备预防和/或治疗结直肠癌药物中的应用
WO2023146843A1 (en) 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023234587A1 (ko) * 2022-05-30 2023-12-07 한국생명공학연구원 베일로넬라 세미날리스 균주, 그의 유래의 배양액 및 그의 항염증 용도
KR102861997B1 (ko) * 2022-05-30 2025-09-22 한국생명공학연구원 베일로넬라 세미날리스 균주, 그의 유래의 배양액 및 그의 항염증 용도
EP4658287A1 (en) * 2023-01-30 2025-12-10 MRM Health N.V. Microbial compositions for treating joint inflammation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101636176A (zh) * 2006-10-27 2010-01-27 哈罗尔·戴维·贡 用于治疗癌症的免疫应答的组织定向性抗原激活
CN107249610A (zh) * 2015-02-19 2017-10-13 纳沙泰尔投资公司 微生物群产生的治疗和预防组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57139090A (en) * 1981-02-19 1982-08-27 Toyama Chem Co Ltd Carcinostatic substance tv-110, its preparation and carcinostatic agent containing the same
JPH04330016A (ja) * 1991-05-01 1992-11-18 Rikagaku Kenkyusho 過酸化脂質低下剤
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
DE69738472T2 (de) * 1997-08-21 2009-01-02 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Neue mutanten der gram-negativen mukosalen bakterien und ihre verwendung als impfstoffe
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
US20050180962A1 (en) * 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
MX2015006491A (es) * 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
US10203329B2 (en) * 2013-09-12 2019-02-12 The Johns Hopkins University Biofilm formation to define risk for colon cancer
US9956282B2 (en) * 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
WO2016040074A1 (en) * 2014-09-11 2016-03-17 Drexel University Maximizing production of hydrogen from waste materials by active removal of hydrogen
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US20180050070A1 (en) * 2015-03-12 2018-02-22 The University Of British Columbia Bacterial compositions and methods of use thereof
KR101734653B1 (ko) * 2015-06-23 2017-05-11 서울대학교산학협력단 아미노글리코시드계 항생제 및 프로바이오틱스를 포함하는 아프타 구내염 예방 또는 치료용 약학적 조성물
AU2018330322A1 (en) * 2017-09-08 2020-03-19 Evelo Biosciences, Inc. Bacterial extracellular vesicles
JP2022537684A (ja) * 2019-06-11 2022-08-29 エヴェロ バイオサイエンシズ,インコーポレーテッド 分泌された微生物細胞外小胞

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101636176A (zh) * 2006-10-27 2010-01-27 哈罗尔·戴维·贡 用于治疗癌症的免疫应答的组织定向性抗原激活
CN107249610A (zh) * 2015-02-19 2017-10-13 纳沙泰尔投资公司 微生物群产生的治疗和预防组合物

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116249540A (zh) * 2020-07-21 2023-06-09 伊夫罗生物科学公司 小韦荣氏球菌菌株作为神经炎性疾病的口服疗法
CN114796264A (zh) * 2021-01-27 2022-07-29 北京北工大科技园有限公司 金络合物在制备治疗新型冠状病毒肺炎的药物中的应用
WO2022160327A1 (zh) * 2021-01-27 2022-08-04 北京工业大学 金络合物在制备治疗新型冠状病毒肺炎的药物中的应用
CN117462662A (zh) * 2022-07-29 2024-01-30 中国科学院上海药物研究所 一种天花粉蛋白融合疫苗及其制备方法和应用
CN116355785A (zh) * 2022-09-29 2023-06-30 南京市儿童医院 一株小韦荣氏球菌及其在制备诊断和治疗口腔鳞状细胞癌产品中的应用
CN116355785B (zh) * 2022-09-29 2026-07-03 南京市儿童医院 一株小韦荣氏球菌及其在制备诊断和治疗口腔鳞状细胞癌产品中的应用
CN115990260A (zh) * 2022-12-09 2023-04-21 中国药科大学 一种用于抗肿瘤的联用组合药物
CN115990260B (zh) * 2022-12-09 2025-07-22 中国药科大学 一种用于抗肿瘤的联用组合药物
TWI859033B (zh) * 2023-12-18 2024-10-11 安益藥業股份有限公司 一種診斷犬科動物胰臟炎的方法與試劑組與一種使用醯基肉鹼作為診斷犬科動物胰臟炎之用途

Also Published As

Publication number Publication date
JP2021512133A (ja) 2021-05-13
US11090341B2 (en) 2021-08-17
CA3090166A1 (en) 2019-08-15
AU2019217526A1 (en) 2020-08-13
WO2019157003A9 (en) 2020-03-19
US20190350987A1 (en) 2019-11-21
EP3749340A1 (en) 2020-12-16
US20210330718A1 (en) 2021-10-28
SA520412543B1 (ar) 2023-12-11
JP7402805B2 (ja) 2023-12-21
TW201945015A (zh) 2019-12-01
WO2019157003A1 (en) 2019-08-15
KR20200118100A (ko) 2020-10-14
CO2020010956A2 (es) 2020-10-30
MX2020008244A (es) 2020-09-25
BR112020015639A2 (pt) 2021-03-30

Similar Documents

Publication Publication Date Title
JP7402805B2 (ja) ベイロネラ(Veillonella)の細菌を使用して癌及び免疫障害を処置するための組成物及び方法
US10702561B2 (en) Pharmaceutical compositions comprising a Blautia strain
US20220211773A1 (en) Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains
US10576111B2 (en) Method of treating cancer using Bifidobacterium animalis ssp. lactis strain PTA-125097
TWI814739B (zh) 細菌胞外囊泡
TWI840334B (zh) 源自普雷沃菌(prevotella)之胞外囊泡
CN111712260A (zh) 使用毛螺菌科细菌治疗免疫病症的组合物和方法
WO2019178490A1 (en) Compositions and methods for treating cancer and inflammation using klebsiella oxytoca
WO2019178487A2 (en) Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae
WO2019178494A1 (en) Compositions and methods for treating cancer and inflammation using tyzzerella nexilis
WO2019169160A1 (en) Compositions and methods for treating cancer using ruminococcus gnavus
WO2019169143A1 (en) Compositions and methods for treating cancer using turicibacter sanguinis
WO2019169138A1 (en) Compositions and methods for treating cancer using paraclostridium benzoelyticum

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20201211